Rumination: Drugs That Cause It, Drugs That Treat It, and What the Evidence Says

For gastrointestinal rumination syndrome, diaphragmatic breathing is the usual first treatment. Baclofen is a medication option when symptoms persist. The most useful medication review also asks whether a drug is causing nausea, reflux or delayed stomach emptying that needs a different approach. [1]

Here, rumination means the repeated return of recently eaten food to the mouth. It is different from repetitive negative thinking, which is also called rumination in mental-health care.

Recognize the pattern before choosing a drug

The Rome IV adult criteria describe recurrent return of recently ingested food, followed by spitting it out or chewing and swallowing it again, without preceding retching. The formal duration criteria are three months of symptoms, beginning at least six months before diagnosis. [2] Those research and diagnostic timeframes are not a reason to postpone assessment of new symptoms.

The pattern involves an abdominal-muscle response after eating that brings food upward. It can occur without the person deliberately choosing to regurgitate. Reflux and rumination can feel similar, and a description such as "food comes back up" does not by itself identify which process is responsible. [3]

Bring concrete details to the appointment: how soon after meals it happens, whether there is nausea or retching, what comes back up, whether swallowing is difficult and whether symptoms occur during sleep. These details are more useful than assuming every episode is acid reflux.

Which medications can resemble or complicate the picture?

A symptom beginning after a new prescription or dose increase is a reason to review that medicine. Timing is a clue, not proof of a rumination diagnosis.

Semaglutide provides a well-documented example. Current Ozempic prescribing information states that it delays gastric emptying and lists gastrointestinal effects including nausea, vomiting, belching and gastroesophageal reflux disease. [4] Those are not interchangeable with a confirmed diagnosis of rumination syndrome.

If symptoms started during dose escalation, record the dose-change date and symptom pattern. The prescriber can assess tolerability and decide whether the treatment plan needs adjustment. There is no single drug-free interval that reliably distinguishes every case of medication-related regurgitation from rumination.

Include opioids, anticholinergic medicines, nitrates, calcium-channel blockers and sedating drugs in the medication list. The practical question is which symptoms or motility effects each may contribute to. Listing these classes as established causes of rumination, without a rumination-specific study, goes beyond what a medication list can establish.

Baclofen: what the controlled trial found

A randomized, double-blind crossover study enrolled 20 adults with suspected rumination and/or supragastric belching. Participants received baclofen 10 mg three times daily or placebo for two weeks, followed by a one-week washout and the alternate treatment. [5]

During post-meal testing, the median number of rumination episodes was eight with baclofen versus 13 with placebo. Overall treatment ratings also favored baclofen, while supragastric belching episodes did not differ significantly. [5]

This supports a specific role for baclofen in rumination. It does not mean that every type of belching or reflux responds in the same way. The 2018 gastroenterology practice update identifies baclofen as a reasonable next step for patients who remain symptomatic after initial treatment. [1]

The study schedule is not a personalized starting regimen. Baclofen's prescribing information identifies drowsiness and dizziness, notes that kidney impairment may require dose reduction, and describes seizures or hallucinations after abrupt withdrawal. [6] Selection, dose changes and discontinuation therefore belong in the prescribing plan.

Tricyclic antidepressants: interpret the combined treatment correctly

A 2020 series followed 44 adults treated with a tricyclic antidepressant plus diaphragmatic breathing and relaxation training. After an average 8.8 months, 90.9% reported some improvement and 45.5% reported at least 80% improvement. [7]

The intervention combined medication with behavioral treatment and did not include a randomized comparison group. These results cannot tell us how much benefit came from the antidepressant alone. They also do not prove a universal threshold at which low doses treat rumination and higher doses cause it.

A clinician may consider a neuromodulator when the person's symptom pattern and other conditions make it appropriate. The treatment goal should be explicit, such as reducing associated discomfort or supporting the broader symptom-management plan, rather than assuming that every patient needs an antidepressant.

Why breathing retraining usually comes first

Diaphragmatic breathing targets the physical muscle pattern involved in rumination. Biofeedback adds a visible signal that helps the person learn to control that pattern.

In a randomized trial, 24 adults were assigned to biofeedback or a placebo condition. After one unrelated withdrawal, 12 biofeedback participants and 11 controls completed three sessions over ten days. Reported daily rumination events fell by about 74% in the biofeedback group versus about 1% in the control group. [8]

This was a structured, coached intervention. It was not simply advice to relax, and the control involved simethicone rather than an active rumination medication. The result supports learning and practicing the technique; it is not a head-to-head comparison proving that breathing outperforms every drug.

Ask the treating team to demonstrate the technique and check that you can reproduce it. Agree on when to practice around meals and what to do when the early sensation of an episode appears. Written instructions can help, but feedback from someone familiar with rumination often makes the practice more useful.

What if breathing helps only partly?

Additional behavioral work can address factors that keep the pattern going. In a proof-of-concept CBT study, ten adults began treatment and eight completed a five-to-eight-session program. Regurgitation decreased during diaphragmatic-breathing work and decreased further when other CBT strategies were added. Six of the eight completers maintained treatment gains at three months. [9]

This was an uncontrolled study, so it does not supply a placebo-adjusted response rate. It does give a practical next step for partial responders: refine the breathing skill and address maintaining patterns rather than assuming the technique has failed after a brief attempt.

What about PPIs, prokinetics and buspirone?

These medicines should be matched to the condition they are intended to treat. Mayo Clinic describes using a proton pump inhibitor when repeated rumination damages the esophagus, to protect its lining while behavioral therapy reduces regurgitation. Reducing acid exposure and stopping the abdominal-pressure pattern are different treatment goals. [10]

Likewise, a treatment directed at delayed gastric emptying should be based on that diagnosis. The baclofen and behavioral trials above do not establish metoclopramide, domperidone or buspirone as equivalent rumination treatments. A response to one of those drugs does not by itself confirm or exclude rumination.

At medication review, ask: which diagnosis is this drug targeting, which symptom should improve, and what result would lead us to reconsider it? This avoids repeatedly escalating acid or nausea medicines without reassessing why food is returning after meals.

When testing and specialist assessment help

An experienced clinician can often diagnose rumination from the history and appropriate medical assessment. When confirmation is needed, high-resolution esophageal manometry with impedance after a meal can demonstrate the pressure-and-flow pattern. It is a targeted investigation rather than a mandatory test for every patient. [1]

Progressive swallowing difficulty, gastrointestinal bleeding, unexplained anemia or substantial unintentional weight loss should prompt evaluation for other causes. New symptoms and a family history of upper gastrointestinal cancer also inform the workup; one age cutoff alone should not dictate an identical test sequence for everyone.

For children, Rome IV uses a separate set of criteria, including a different duration requirement. [2] Pediatric care should address eating, growth and family participation. Adults with an eating disorder or intellectual disability may also need the behavioral approach adapted to their circumstances.

Track the outcome that matters

A short record can make follow-up more productive:

The aim is fewer episodes, comfortable eating and a sustainable treatment plan. That requires identifying the actual pattern and checking the response, rather than labeling every regurgitation episode as a drug side effect or adding medications without a defined target.

References

1. Halland, Pandolfino and Barba. Diagnosis and treatment of rumination syndrome: clinical practice update, 2018.
2. Rome Foundation. Rome IV diagnostic criteria for adult and pediatric rumination syndrome.
3. UEG and ESNM. European guideline on chronic nausea and vomiting, including rumination syndrome, 2025.
4. Novo Nordisk. Ozempic prescribing information.
5. Pauwels and colleagues. Randomized placebo-controlled crossover trial of baclofen for rumination, 2018.
6. DailyMed. Baclofen tablet prescribing information.
7. Robles and colleagues. Tricyclic antidepressant plus diaphragmatic breathing outcomes, 2020.
8. Barba and colleagues. Randomized placebo-controlled trial of biofeedback for rumination, 2016.
9. Murray and colleagues. CBT added to diaphragmatic breathing: proof-of-concept trial, 2021.
10. Mayo Clinic. Rumination syndrome diagnosis and treatment, 2025.